Pennant Group sees FY25 adjusted EPS $1.09-$1.15, consensus $1.13

Management is providing updated 2025 annual guidance as follows: total revenue is anticipated to be between $852.8 million and $887.6 million; full year 2025 adjusted earnings per diluted share is anticipated to be between $1.09 and $1.15; and full year 2025 adjusted EBITDA is anticipated to be between $69.1 million and $72.7 million. Guerisoli remarked, “Our earnings guidance midpoint of $1.12 represents 19.1% growth on our 2024 adjusted earnings per share and 53.4% growth over 2023 results. Our guidance update is based on the momentum across our segments, the capability of our local leaders to continue to drive growth, and the untapped potential within our existing operations.” The Company’s updated 2025 annual guidance is based on diluted weighted average shares outstanding of approximately 35.7 million and a 26.0% effective tax rate. The guidance includes additional expenses in anticipation of the transaction with UnitedHealth Group and Amedisys, but no additional earnings because of the uncertainty surrounding the timing of our closing on that transaction. The guidance assumes, among other things, reimbursement rate adjustments and no unannounced acquisitions. It excludes the tax-effected costs at start-up operations, share-based compensation, acquisition-related costs, and gain on disposition of assets and impairments. Revenue consensus $852.11M.